Friday, April 5, 2013
Pfizer suffers big setbacks on appeal in three Neurontin cases
Health plan plaintiffs have scored big in a trio of appellate rulings in multidistrict litigation over Pfizer's off-label marketing of Neurontin, a drug approved by the U.S. Food and Drug Administration as an anti-seizure agent for epilepsy sufferers. The First Circuit affirmed a $142 million verdict against Pfizer and revived class certification plus racketeering and state law claims.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment